FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897737935> ?p ?o ?g. }

• W2897737935 abstract "Glucocorticoids (GC) are potent anti-inflammatory and immunosuppressive drugs which are used successfully to treat many disorders, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, myositis, systemic lupus erythematodes and other rheumatic diseases. However, these drugs also have the potential to cause severe adverse effects, particularly if high doses are used for prolonged periods. Therefore, the benefits of GC therapy must be balanced against the potential risks. Key strategies to achieve this goal include (i) following guideline recommendations regarding GC therapy dosing, monitoring for potential adverse events, and adverse event prevention and management, (ii) using or developing new therapeutic advances to improve the therapeutic balance. The EULAR Glucocorticoid Task Force has already published several recommendations over the last years such as those on the standardised nomenclature for GC dosages and treatment regimens, on the management of systemic GC therapy in rheumatic diseases, and on monitoring adverse events of low-dose GC therapy. Recent work of this group dealt with the question under which conditions long-term treatment with GC has an acceptably low level of harm. As a result, the task force members agreed that the risk of harm is low for the majority of patients at long-term dosages of ≤5 mg prednisone equivalent per day, whereas at dosages of >10 mg/day the risk of harm is elevated. At dosages between >5 and ≤10 mg/day, patient-specific characteristics determine the risk of harm. This means general and glucocorticoid-associated risk factors and protective factors such as a healthy lifestyle should be taken into account when evaluating the actual and future risk. Another new information on the use of GCs has been recently provided by EULAR 2016 update of RA recommendations: “Short-term GCs should be considered when initiating or changing csDMARDs, in different dose regimens and routes of administration, but should be tapered as rapidly as clinically feasible.” This wording does acknowledge that there are several different regimens for oral use, intramuscular injection, and intravenous pulse therapy. It is now also being stated more clearly that GCs should be given as bridging therapy together with csDMARDs, either as part of the initial strategy or subsequently if this has failed. In contrast, GCs are usually not needed as a bridging therapy when bDMARDs or tsDMARDs are used. This recommendations reconfirms that GCs should be gradually reduced and ultimately stopped, ideally within 3 to 6 months. Finally, the role of GCs in the management of polymyalgia rheumatica as has been described and discussed by the recent EULAR/ACR recommendations will be briefly discussed. Disclosure of Interest F. Buttgereit Grant/research support from: Mundipharma, Horizon, Pfizer, Consultant for: Horizon, Pfizer, Speakers bureau: Horizon, Pfizer," @default.
• W2897737935 created "2018-10-26" @default.
• W2897737935 creator A5058094909 @default.
• W2897737935 date "2018-06-01" @default.
• W2897737935 modified "2023-09-30" @default.
• W2897737935 title "SP0160 2018 eular recommendations for the use of glucocorticoid therapy" @default.
• W2897737935 doi "https://doi.org/10.1136/annrheumdis-2018-eular.7690" @default.
• W2897737935 hasPublicationYear "2018" @default.
• W2897737935 type Work @default.
• W2897737935 sameAs 2897737935 @default.
• W2897737935 citedByCount "0" @default.
• W2897737935 crossrefType "proceedings-article" @default.
• W2897737935 hasAuthorship W2897737935A5058094909 @default.
• W2897737935 hasBestOaLocation W28977379351 @default.
• W2897737935 hasConcept C126322002 @default.
• W2897737935 hasConcept C142724271 @default.
• W2897737935 hasConcept C162156334 @default.
• W2897737935 hasConcept C177713679 @default.
• W2897737935 hasConcept C197934379 @default.
• W2897737935 hasConcept C2776015282 @default.
• W2897737935 hasConcept C2776712624 @default.
• W2897737935 hasConcept C2777288759 @default.
• W2897737935 hasConcept C2777575956 @default.
• W2897737935 hasConcept C2778720950 @default.
• W2897737935 hasConcept C2779134260 @default.
• W2897737935 hasConcept C2780079024 @default.
• W2897737935 hasConcept C2780182762 @default.
• W2897737935 hasConcept C2780841215 @default.
• W2897737935 hasConcept C71924100 @default.
• W2897737935 hasConceptScore W2897737935C126322002 @default.
• W2897737935 hasConceptScore W2897737935C142724271 @default.
• W2897737935 hasConceptScore W2897737935C162156334 @default.
• W2897737935 hasConceptScore W2897737935C177713679 @default.
• W2897737935 hasConceptScore W2897737935C197934379 @default.
• W2897737935 hasConceptScore W2897737935C2776015282 @default.
• W2897737935 hasConceptScore W2897737935C2776712624 @default.
• W2897737935 hasConceptScore W2897737935C2777288759 @default.
• W2897737935 hasConceptScore W2897737935C2777575956 @default.
• W2897737935 hasConceptScore W2897737935C2778720950 @default.
• W2897737935 hasConceptScore W2897737935C2779134260 @default.
• W2897737935 hasConceptScore W2897737935C2780079024 @default.
• W2897737935 hasConceptScore W2897737935C2780182762 @default.
• W2897737935 hasConceptScore W2897737935C2780841215 @default.
• W2897737935 hasConceptScore W2897737935C71924100 @default.
• W2897737935 hasLocation W28977379351 @default.
• W2897737935 hasOpenAccess W2897737935 @default.
• W2897737935 hasPrimaryLocation W28977379351 @default.
• W2897737935 hasRelatedWork W156931934 @default.
• W2897737935 hasRelatedWork W2006019631 @default.
• W2897737935 hasRelatedWork W2024282002 @default.
• W2897737935 hasRelatedWork W2027065448 @default.
• W2897737935 hasRelatedWork W2057687448 @default.
• W2897737935 hasRelatedWork W2106824479 @default.
• W2897737935 hasRelatedWork W2107720679 @default.
• W2897737935 hasRelatedWork W2292748966 @default.
• W2897737935 hasRelatedWork W2410833014 @default.
• W2897737935 hasRelatedWork W2474058706 @default.
• W2897737935 hasRelatedWork W2554635654 @default.
• W2897737935 hasRelatedWork W2555237241 @default.
• W2897737935 hasRelatedWork W2622691876 @default.
• W2897737935 hasRelatedWork W2749480743 @default.
• W2897737935 hasRelatedWork W2767052580 @default.
• W2897737935 hasRelatedWork W2790278885 @default.
• W2897737935 hasRelatedWork W2897058468 @default.
• W2897737935 hasRelatedWork W2951610174 @default.
• W2897737935 hasRelatedWork W2953318722 @default.
• W2897737935 hasRelatedWork W3174911910 @default.
• W2897737935 isParatext "false" @default.
• W2897737935 isRetracted "false" @default.
• W2897737935 magId "2897737935" @default.
• W2897737935 workType "article" @default.